Dr. Kris Talks About Defining Biomarkers

Mark G. Kris, MD
Published: Tuesday, Jul 05, 2011

Mark G. Kris, MD, chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center discusses the importance of defining the term biomarker.

He explains that the term is too broad and can mean more than just a gene; it can be proteins, epigenetic changes, methylation changes, transcription changes, and many other kinds, narrowing in on the precise type determines the type and complexity of testing.

Dr. Kris says it's important to be precise because the complexity of the testing and the liability of the testing changes quite a bit depending on what biomarker is being looked at.
Mark G. Kris, MD, chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center discusses the importance of defining the term biomarker.

He explains that the term is too broad and can mean more than just a gene; it can be proteins, epigenetic changes, methylation changes, transcription changes, and many other kinds, narrowing in on the precise type determines the type and complexity of testing.

Dr. Kris says it's important to be precise because the complexity of the testing and the liability of the testing changes quite a bit depending on what biomarker is being looked at.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x